Deciphera Pharmaceuticals LLC   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Waltham MA United States (2003)

Organization Overview

First Clinical Trial
2009
NCT00827138
First Marketed Drug
2020
ripretinib (Qinlock)
First NDA Approval
2020
ripretinib (Qinlock)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Deciphera Pharmaceuticals LLC | DECIPHERA PHARMACEUTICALS LLC | DECIPHERA PHARMS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Gastrointestinal Stromal Tumors (Phase 3)

Giant Cell Tumor of Tendon Sheath (Phase 1)

Giant Cell Tumors (Phase 1)

Leukemia (Phase 1)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Mastocytosis (Phase 1)

Mastocytosis, Systemic (Phase 1)

Neoplasms (Phase 2)

Synovitis, Pigmented Villonodular (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 14